Margetuximab for HER2-Positive Breast Cancer
September 21, 2021

In an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.

FDA Grants Accelerated Approval to Tisotumab Vedotin in Recurrent Or Metastatic Cervical Cancer
September 20, 2021

Tisotumab vedotin may now be used to treat patients with recurrent or metastatic cervical cancer after the FDA's decision to grant the agent an accelerated approval.

Possible Association Noted Between Tumor Immunogenicity and Survival Outcomes in HR+, HER2+ Early Breast Cancer Following Neoadjuvent T-DM1 De-Escalation
September 20, 2021

Investigators believe the use of biomarkers can determine the results of de-escalated neoadjuvant T-DM1 in HR-positive/HER2-positive early breast cancer.